Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma

117Citations
Citations of this article
63Readers
Mendeley users who have this article in their library.

Abstract

Background: There is a strong rationale in the use of antiangiogenic therapy in the management of adrenocortical carcinoma (ACC). Metronomic administration of chemotherapy and antiangiogenic drugs can be synergistic in targeting endothelial cells. Objective:We assessed the activity of sorafenib plus metronomic paclitaxel as second/third-line therapy in advanced ACC patients. We also tested the activity of sorafenib and paclitaxel against NCI-H295R in vitro. Design: Multicenter, prospective phase II trial. Setting: Referral centers for ACC. Methods: Twenty-five consecutive metastatic ACC patients who progressed after mitotane plus one or two chemotherapy lines were planned to be enrolled. The patients received a combination of i.v. paclitaxel (60 mg/m2 every week) and oral sorafenib (400 mg twice a day) till progression. The primary aim was to measure the progression-free survival rate after 4 months and the secondary aims were to assess the objective response rate and toxicity. Results: Tumor progression was observed in nine evaluable patients at the first assessment. These results led to the premature interruption of the trial. The treatment was well tolerated. The most relevant toxicities were fatigue, being grade 2 or 3 in four patients, and hypophosphatemia, being grade 3 in three patients. In the in vitro study, sorafenib impaired the viability of H295R cells with dose-response and time-response relationships. The in vitro sorafenib activity was not increased in combination with paclitaxel. Conclusions: Despite the in vitro activity, sorafenib plus weekly paclitaxel is an inactive salvage treatment in patients with advanced ACC and should not be recommended. © 2012 European Society of Endocrinology.

References Powered by Scopus

New guidelines to evaluate the response to treatment in solid tumors

14923Citations
N/AReaders
Get full text

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

3735Citations
N/AReaders
Get full text

Optimal two-stage designs for phase II clinical trials

3259Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Adrenocortical carcinoma

677Citations
N/AReaders
Get full text

Combination chemotherapy in advanced adrenocortical carcinoma

657Citations
N/AReaders
Get full text

European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors

621Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Berruti, A., Sperone, P., Ferrero, A., Germano, A., Ardito, A., Priola, A. M., … Terzolo, M. (2012). Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. European Journal of Endocrinology, 166(3), 451–458. https://doi.org/10.1530/EJE-11-0918

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 20

57%

Researcher 10

29%

Professor / Associate Prof. 5

14%

Readers' Discipline

Tooltip

Medicine and Dentistry 33

70%

Agricultural and Biological Sciences 8

17%

Biochemistry, Genetics and Molecular Bi... 5

11%

Physics and Astronomy 1

2%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free